Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 288 entries
Sorted by: Best Match Show Resources per page
Is diversification rate related to climatic niche width?

STEM and diversification

Baselga A, Gómez‐Rodríguez C.
GSID: V_gJO_SIOT8J
C Gómez‐Rodríguez, A Baselga… - Global Ecology and …, 2015 - Wiley Online Library

… Diversification rates for each family were initially estimated given the number of species in the family and the family's stem age (Fig. 2). The number of species belonging to each family …

Cite
Gómez‐Rodríguez, C., Baselga, A., & Wiens, J. J. (2015). Is diversification rate related to climatic niche width?. Global Ecology and Biogeography, 24(4), 383-395.
Gómez‐Rodríguez, Carola, Andrés Baselga, and John J. Wiens. "Is diversification rate related to climatic niche width?." Global Ecology and Biogeography 24.4 (2015): 383-395.
Copy Download .nbib Format: MLA
Ludwig Heilmeyer.

Haematologica

Baserga A.
PMID: 4993481
Haematologica. 1970;55(2):163.

No abstract available.

Cite
Baserga A. Ludwig Heilmeyer. Haematologica. 1970;55(2):163
Baserga, A. (1970). Ludwig Heilmeyer. Haematologica, 55(2), 163.
Baserga, A. "Ludwig Heilmeyer." Haematologica vol. 55,2 (1970): 163.
Baserga A. Ludwig Heilmeyer. Haematologica. 1970;55(2):163. PMID: 4993481.
Copy Download .nbib Format: NLM
Structural, dynamical, and transport properties of the hydrated halides: How do At(-) bulk properties compare with those of the other halides, from F(-) to I(-)?.

The Journal of chemical physics

Réal F, Gomes AS, Guerrero Martínez YO, Ayed T, Galland N, Masella M, Vallet V.
PMID: 27036467
J Chem Phys. 2016 Mar 28;144(12):124513. doi: 10.1063/1.4944613.

The properties of halides from the lightest, fluoride (F(-)), to the heaviest, astatide (At(-)), have been studied in water using a polarizable force-field approach based on molecular dynamics (MD) simulations at the 10 ns scale. The selected force-field explicitly...

Cite
Réal F, Gomes AS, Guerrero Martínez YO, et al. Structural, dynamical, and transport properties of the hydrated halides: How do At(-) bulk properties compare with those of the other halides, from F(-) to I(-)?. J Chem Phys. 2016;144(12):124513doi: 10.1063/1.4944613.
Réal, F., Gomes, A. S., Guerrero Martínez, Y. O., Ayed, T., Galland, N., Masella, M., & Vallet, V. (2016). Structural, dynamical, and transport properties of the hydrated halides: How do At(-) bulk properties compare with those of the other halides, from F(-) to I(-)?. The Journal of chemical physics, 144(12), 124513. https://doi.org/10.1063/1.4944613
Réal, Florent, et al. "Structural, dynamical, and transport properties of the hydrated halides: How do At(-) bulk properties compare with those of the other halides, from F(-) to I(-)?." The Journal of chemical physics vol. 144,12 (2016): 124513. doi: https://doi.org/10.1063/1.4944613
Réal F, Gomes AS, Guerrero Martínez YO, Ayed T, Galland N, Masella M, Vallet V. Structural, dynamical, and transport properties of the hydrated halides: How do At(-) bulk properties compare with those of the other halides, from F(-) to I(-)?. J Chem Phys. 2016 Mar 28;144(12):124513. doi: 10.1063/1.4944613. PMID: 27036467.
Copy Download .nbib Format: NLM
Monitoring Atrial Fibrillation After Catheter Ablation.

Journal of atrial fibrillation

Forleo GB, Casella M, Dello Russo A, Moltrasio M, Fassini G, Tesauro M, Tondo C.
PMID: 27957062
J Atr Fibrillation. 2014 Apr 30;6(6):1040. doi: 10.4022/jafib.1040. eCollection 2014.

Although catheter ablation is an effective treatment for recurrent atrial fibrillation (AF), there is no consensus on the definition of success or follow-up strategies. Symptoms are the major motivation for undergoing catheter ablation in patients with AF, however it...

Cite
Forleo GB, Casella M, Dello Russo A, et al. Monitoring Atrial Fibrillation After Catheter Ablation. J Atr Fibrillation. 2014;6(6):1040doi: 10.4022/jafib.1040.
Forleo, G. B., Casella, M., Dello Russo, A., Moltrasio, M., Fassini, G., Tesauro, M., & Tondo, C. (2014). Monitoring Atrial Fibrillation After Catheter Ablation. Journal of atrial fibrillation, 6(6), 1040. https://doi.org/10.4022/jafib.1040
Forleo, Giovanni B, et al. "Monitoring Atrial Fibrillation After Catheter Ablation." Journal of atrial fibrillation vol. 6,6 (2014): 1040. doi: https://doi.org/10.4022/jafib.1040
Forleo GB, Casella M, Dello Russo A, Moltrasio M, Fassini G, Tesauro M, Tondo C. Monitoring Atrial Fibrillation After Catheter Ablation. J Atr Fibrillation. 2014 Apr 30;6(6):1040. doi: 10.4022/jafib.1040. eCollection 2014. PMID: 27957062; PMCID: PMC5135239.
Copy Download .nbib Format: NLM
The reductive phase of Rhodobacter sphaeroides cytochrome c oxidase disentangled by CO ligation.

Physical chemistry chemical physics : PCCP

Mohrmann H, Dragelj J, Baserga F, Knapp EW, Stripp ST, Heberle J.
PMID: 29067359
Phys Chem Chem Phys. 2017 Oct 25; doi: 10.1039/c7cp06480b. Epub 2017 Oct 25.

Cytochrome c oxidase (CcO) is a membrane protein of the respiratory chain that catalytically reduces molecular oxygen (O

Cite
Mohrmann H, Dragelj J, Baserga F, et al. The reductive phase of Rhodobacter sphaeroides cytochrome c oxidase disentangled by CO ligation. Phys Chem Chem Phys. 2017;doi: 10.1039/c7cp06480b.
Mohrmann, H., Dragelj, J., Baserga, F., Knapp, E. W., Stripp, S. T., & Heberle, J. (2017). The reductive phase of Rhodobacter sphaeroides cytochrome c oxidase disentangled by CO ligation. Physical chemistry chemical physics : PCCP, . https://doi.org/10.1039/c7cp06480b
Mohrmann, Hendrik, et al. "The reductive phase of Rhodobacter sphaeroides cytochrome c oxidase disentangled by CO ligation." Physical chemistry chemical physics : PCCP vol. (2017). doi: https://doi.org/10.1039/c7cp06480b
Mohrmann H, Dragelj J, Baserga F, Knapp EW, Stripp ST, Heberle J. The reductive phase of Rhodobacter sphaeroides cytochrome c oxidase disentangled by CO ligation. Phys Chem Chem Phys. 2017 Oct 25; doi: 10.1039/c7cp06480b. Epub 2017 Oct 25. PMID: 29067359.
Copy Download .nbib Format: NLM
A modified human ELISPOT assay to detect specific responses to primary tumor cell targets.

Journal of translational medicine

Malyguine A, Strobl SL, Shafer-Weaver KA, Ulderich T, Troke A, Baseler M, Kwak LW, Neelapu SS.
PMID: 15050026
J Transl Med. 2004 Mar 29;2(1):9. doi: 10.1186/1479-5876-2-9.

BACKGROUND: The desired outcome of cancer vaccination is to induce a potent T cell response which can specifically recognize and eliminate autologous tumor cells in vivo. Accordingly, immunological assays that demonstrate recognition of native tumor cells (tumor-specific) may be...

Cite
Malyguine A, Strobl SL, Shafer-Weaver KA, et al. A modified human ELISPOT assay to detect specific responses to primary tumor cell targets. J Transl Med. 2004;2(1):9doi: 10.1186/1479-5876-2-9.
Malyguine, A., Strobl, S. L., Shafer-Weaver, K. A., Ulderich, T., Troke, A., Baseler, M., Kwak, L. W., & Neelapu, S. S. (2004). A modified human ELISPOT assay to detect specific responses to primary tumor cell targets. Journal of translational medicine, 2(1), 9. https://doi.org/10.1186/1479-5876-2-9
Malyguine, Anatoli, et al. "A modified human ELISPOT assay to detect specific responses to primary tumor cell targets." Journal of translational medicine vol. 2,1 (2004): 9. doi: https://doi.org/10.1186/1479-5876-2-9
Malyguine A, Strobl SL, Shafer-Weaver KA, Ulderich T, Troke A, Baseler M, Kwak LW, Neelapu SS. A modified human ELISPOT assay to detect specific responses to primary tumor cell targets. J Transl Med. 2004 Mar 29;2(1):9. doi: 10.1186/1479-5876-2-9. PMID: 15050026; PMCID: PMC415560.
Copy Download .nbib Format: NLM
On the Eberthian liver diseases; pathogenetic, clinical and therapeutic considerations.

Minerva medica

BASERGA A, ASTALDI G.
PMID: 18100636
Minerva Med. 1948 Nov 10;39(45):491-8.

No abstract available.

Cite
BASERGA A, ASTALDI G. Sulle epatopatie eberthiane; considerazioni patogenetiche, cliniche e terapeutiche. On the Eberthian liver diseases; pathogenetic, clinical and therapeutic considerations. Minerva Med. 1948;39(45):491-8
BASERGA, A., & ASTALDI, G. (1948). Sulle epatopatie eberthiane; considerazioni patogenetiche, cliniche e terapeutiche. On the Eberthian liver diseases; pathogenetic, clinical and therapeutic considerations. Minerva medica, 39(45), 491-8.
BASERGA, A, and ASTALDI, G. "Sulle epatopatie eberthiane; considerazioni patogenetiche, cliniche e terapeutiche." On the Eberthian liver diseases; pathogenetic, clinical and therapeutic considerations. Minerva medica vol. 39,45 (1948): 491-8.
BASERGA A, ASTALDI G. Sulle epatopatie eberthiane; considerazioni patogenetiche, cliniche e terapeutiche. On the Eberthian liver diseases; pathogenetic, clinical and therapeutic considerations. Minerva Med. 1948 Nov 10;39(45):491-8. Italian. PMID: 18100636.
Copy Download .nbib Format: NLM
Baseline NT-Pro-BNP levels and arrhythmia recurrence in outpatients undergoing elective cardioversion of persistent atrial fibrillation: a survival analysis.

Indian pacing and electrophysiology journal

Sanna T, Sonaglioni A, Pieroni M, Dello Russo A, Pelargonio G, Casella M, Zichichi E, La Torre G, Narducci ML, Bellocci F.
PMID: 19165355
Indian Pacing Electrophysiol J. 2009;9(1):15-24. Epub 2009 Jan 07.

BACKGROUND: Atrial fibrillation (AF) is the most common arrhythmia encountered in clinical practice. Elective electrical cardioversion is often performed in patients with persistent AF to attempt sinus rhythm (SR) restoration. However, AF recurrences are frequent after successful cardioversion and...

Cite
Sanna T, Sonaglioni A, Pieroni M, et al. Baseline NT-Pro-BNP levels and arrhythmia recurrence in outpatients undergoing elective cardioversion of persistent atrial fibrillation: a survival analysis. Indian Pacing Electrophysiol J. 2009;9(1):15-24
Sanna, T., Sonaglioni, A., Pieroni, M., Dello Russo, A., Pelargonio, G., Casella, M., Zichichi, E., La Torre, G., Narducci, M. L., & Bellocci, F. (2009). Baseline NT-Pro-BNP levels and arrhythmia recurrence in outpatients undergoing elective cardioversion of persistent atrial fibrillation: a survival analysis. Indian pacing and electrophysiology journal, 9(1), 15-24.
Sanna, Tommaso, et al. "Baseline NT-Pro-BNP levels and arrhythmia recurrence in outpatients undergoing elective cardioversion of persistent atrial fibrillation: a survival analysis." Indian pacing and electrophysiology journal vol. 9,1 (2009): 15-24.
Sanna T, Sonaglioni A, Pieroni M, Dello Russo A, Pelargonio G, Casella M, Zichichi E, La Torre G, Narducci ML, Bellocci F. Baseline NT-Pro-BNP levels and arrhythmia recurrence in outpatients undergoing elective cardioversion of persistent atrial fibrillation: a survival analysis. Indian Pacing Electrophysiol J. 2009;9(1):15-24. Epub 2009 Jan 07. PMID: 19165355; PMCID: PMC2615058.
Copy Download .nbib Format: NLM
[Diagnostic progress].

Il Progresso medico

BASERGA A.
PMID: 14949147
Prog Med (Napoli). 1952 May 31;8(10):289-301.

No abstract available.

Cite
BASERGA A. Il progresso dell'indagine diagnostica. [Diagnostic progress]. Prog Med (Napoli). 1952;8(10):289-301
BASERGA, A. (1952). Il progresso dell'indagine diagnostica. [Diagnostic progress]. Il Progresso medico, 8(10), 289-301.
BASERGA, A. "Il progresso dell'indagine diagnostica." [Diagnostic progress]. Il Progresso medico vol. 8,10 (1952): 289-301.
BASERGA A. Il progresso dell'indagine diagnostica. [Diagnostic progress]. Prog Med (Napoli). 1952 May 31;8(10):289-301. Undetermined. PMID: 14949147.
Copy Download .nbib Format: NLM
Trastuzumab, a humanized anti-HER2 monoclonal antibody, for the treatment of breast cancer.

Drugs of today (Barcelona, Spain : 1998)

Albanell J, Baselga J.
PMID: 12973420
Drugs Today (Barc). 1999 Dec;35(12):931-46.

The HER2/neu gene encodes a 185 kDa transmembrane receptor (HER2) that belongs to the epidermal growth factor receptor family and has intrinsic tyrosine kinase activity. HER2 is overexpressed in 25-30% of breast cancers and is suggested to have a...

Cite
Albanell J, Baselga J. Trastuzumab, a humanized anti-HER2 monoclonal antibody, for the treatment of breast cancer. Drugs Today (Barc). 1999;35(12):931-46
Albanell, J., & Baselga, J. (1999). Trastuzumab, a humanized anti-HER2 monoclonal antibody, for the treatment of breast cancer. Drugs of today (Barcelona, Spain : 1998), 35(12), 931-46.
Albanell, J, and Baselga, J. "Trastuzumab, a humanized anti-HER2 monoclonal antibody, for the treatment of breast cancer." Drugs of today (Barcelona, Spain : 1998) vol. 35,12 (1999): 931-46.
Albanell J, Baselga J. Trastuzumab, a humanized anti-HER2 monoclonal antibody, for the treatment of breast cancer. Drugs Today (Barc). 1999 Dec;35(12):931-46. PMID: 12973420.
Copy Download .nbib Format: NLM
Mutations in the VEGFR3 signaling pathway explain 36% of familial lymphedema.

Molecular syndromology

Mendola A, Schlögel MJ, Ghalamkarpour A, Irrthum A, Nguyen HL, Fastré E, Bygum A, van der Vleuten C, Fagerberg C, Baselga E, Quere I, Mulliken JB, Boon LM, Brouillard P, Vikkula M.
PMID: 24167460
Mol Syndromol. 2013 Sep;4(6):257-66. doi: 10.1159/000354097. Epub 2013 Aug 21.

Lymphedema is caused by dysfunction of lymphatic vessels, leading to disabling swelling that occurs mostly on the extremities. Lymphedema can be either primary (congenital) or secondary (acquired). Familial primary lymphedema commonly segregates in an autosomal dominant or recessive manner....

Cite
Mendola A, Schlögel MJ, Ghalamkarpour A, et al. Mutations in the VEGFR3 signaling pathway explain 36% of familial lymphedema. Mol Syndromol. 2013;4(6):257-66doi: 10.1159/000354097.
Mendola, A., Schlögel, M. J., Ghalamkarpour, A., Irrthum, A., Nguyen, H. L., Fastré, E., Bygum, A., van der Vleuten, C., Fagerberg, C., Baselga, E., Quere, I., Mulliken, J. B., Boon, L. M., Brouillard, P., Vikkula, M. (2013). Mutations in the VEGFR3 signaling pathway explain 36% of familial lymphedema. Molecular syndromology, 4(6), 257-66. https://doi.org/10.1159/000354097
Mendola, A, et al. "Mutations in the VEGFR3 signaling pathway explain 36% of familial lymphedema." Molecular syndromology vol. 4,6 (2013): 257-66. doi: https://doi.org/10.1159/000354097
Mendola A, Schlögel MJ, Ghalamkarpour A, Irrthum A, Nguyen HL, Fastré E, Bygum A, van der Vleuten C, Fagerberg C, Baselga E, Quere I, Mulliken JB, Boon LM, Brouillard P, Vikkula M. Mutations in the VEGFR3 signaling pathway explain 36% of familial lymphedema. Mol Syndromol. 2013 Sep;4(6):257-66. doi: 10.1159/000354097. Epub 2013 Aug 21. PMID: 24167460; PMCID: PMC3776465.
Copy Download .nbib Format: NLM
Manifold benefits of choosing a minimally fluoroscopic catheter ablation approach.

World journal of cardiology

Casella M, Dello Russo A, Fassini G, Andreini D, De Iuliis P, Mushtaq S, Bartoletti S, Riva S, Tondo C.
PMID: 23538845
World J Cardiol. 2013 Feb 26;5(2):8-11. doi: 10.4330/wjc.v5.i2.8.

We report the case of a 14-year-old boy with ventricular preexcitation. A standard, fluoroscopy guided, ablation procedure was successfully performed in a postero-midseptal region with a total fluoroscopy time of about 45 min (2430 cGy.cm(2)). A few hours after...

Cite
Casella M, Dello Russo A, Fassini G, et al. Manifold benefits of choosing a minimally fluoroscopic catheter ablation approach. World J Cardiol. 2013;5(2):8-11doi: 10.4330/wjc.v5.i2.8.
Casella, M., Dello Russo, A., Fassini, G., Andreini, D., De Iuliis, P., Mushtaq, S., Bartoletti, S., Riva, S., & Tondo, C. (2013). Manifold benefits of choosing a minimally fluoroscopic catheter ablation approach. World journal of cardiology, 5(2), 8-11. https://doi.org/10.4330/wjc.v5.i2.8
Casella, Michela, et al. "Manifold benefits of choosing a minimally fluoroscopic catheter ablation approach." World journal of cardiology vol. 5,2 (2013): 8-11. doi: https://doi.org/10.4330/wjc.v5.i2.8
Casella M, Dello Russo A, Fassini G, Andreini D, De Iuliis P, Mushtaq S, Bartoletti S, Riva S, Tondo C. Manifold benefits of choosing a minimally fluoroscopic catheter ablation approach. World J Cardiol. 2013 Feb 26;5(2):8-11. doi: 10.4330/wjc.v5.i2.8. PMID: 23538845; PMCID: PMC3609011.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 288 entries